Geode Capital Management LLC Has $889.05 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Geode Capital Management LLC raised its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,521,147 shares of the medical research company's stock after purchasing an additional 284,918 shares during the quarter. Geode Capital Management LLC owned 2.29% of Edwards Lifesciences worth $889,050,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $40,000. Finally, JFS Wealth Advisors LLC raised its position in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after purchasing an additional 166 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded up $0.16 on Thursday, hitting $73.97. The stock had a trading volume of 3,748,126 shares, compared to its average volume of 4,649,521. The company has a market capitalization of $43.63 billion, a price-to-earnings ratio of 10.67, a price-to-earnings-growth ratio of 3.52 and a beta of 1.12. The firm's 50 day moving average price is $69.09 and its 200-day moving average price is $74.19. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter last year, the company posted $0.59 EPS. The company's quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EW. Barclays lifted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an "overweight" rating in a research note on Monday, December 2nd. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. The Goldman Sachs Group increased their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Finally, Royal Bank of Canada lifted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research note on Thursday, December 5th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $78.65.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock worth $2,323,150 over the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.